Regeneron stock: CytomX reports 5 million dollar milestone payment
Published on 11/18/2026 at 14:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegeneron partnership reaches milestone
- CytomX said a preclinical milestone in its Regeneron collaboration triggers a 5 million US dollar payment.
- The companies are developing conditionally activated bispecific antibodies for cancer treatment.
- CytomX may receive up to approximately 4 billion US dollars in potential payments under the expanded collaboration.
On November 17, CytomX Therapeutics said a preclinical milestone in its collaboration with Regeneron had been achieved, triggering a 5 million US dollar payment. The announcement was published by CytomX Therapeutics at 16:15 Eastern Time.
The collaboration combines CytomX's PROBODY therapeutic masking technology with Regeneron's Veloci-Bi bispecific antibody platform. The companies aim to develop treatments that remain inactive in systemic circulation and are activated by proteases concentrated in the tumor microenvironment.
Preclinical work sets the next stage
CytomX said the milestone came from one of the lead programs in the partnership. The announcement did not identify the program or provide clinical efficacy data, so the update marks progress in discovery and preclinical development rather than a clinical-stage readout.
Under the agreement, Regeneron is responsible for funding preclinical and clinical development as well as commercialization activities. CytomX is eligible for target nomination, preclinical, clinical, regulatory and commercial milestone payments totaling up to approximately 4 billion US dollars across the expanded collaboration, in addition to tiered royalties on potential global net sales.
The partnership began in 2022 and was expanded in June 2026. CytomX Chief Executive Sean McCarthy said the milestone represented the translation of promising science toward the clinic and highlighted the potential of combining the two companies' technologies. The statement describes a development path, not an approved product or a clinical outcome.
Investor context
Regeneron stock traded at 869.00 euros on Lang & Schwarz at 14:12:32 CET on Wednesday, November 18, 2026. The collaboration adds another oncology pipeline development to a period that has also included recent company updates on Libtayo, baloncibart and CIDEBsiRNA.
Regeneron Pharmaceuticals
- ISIN: US75886F1075
- Ticker: REGN
- Primary market: Nasdaq
- Lang & Schwarz quote: 869.00 euros at 14:12:32 CET on November 18, 2026
- Collaboration milestone: 5 million US dollars
The broader US equity market is covered in the S&P 500 market overview.
